3α,4β-dihydroxy-5β-androstan-17-one | 434939-07-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子
• 英文名称: 3α,4β-dihydroxy-5β-androstan-17-one
• 英文别名: 3alpha,4beta-Dihydroxy-5beta-androstan-17-one；(3R,4R,5S,8R,9S,10R,13S,14S)-3,4-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
• CAS: 434939-07-8
• 化学式: C₁₉H₃₀O₃
• 分子量: 306.445
• InChiKey: RFMKWBMPDNCUNR-YKWLFNOOSA-N

物化性质

• 沸点：
  434.4±45.0 °C(Predicted)
• 密度：
  1.158±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3α,4β-dihydroxy-5β-androstan-17-one 在 二甲基亚砜 、 三乙胺 、 三氟乙酸酐 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 3-hydroxy-5β-androst-2-ene-4,17-dione
  参考文献：
  名称：

  福美斯坦 5β-环氧化物前体异常环裂解的 X 射线和氘标记研究

  摘要：

  抗肿瘤类固醇福美烷 (4-OHA) 5 的新聚合合成已从 5 α-和 5 β-androst-3-en-17-one 1a 和 1b 的易于获得的差向异构混合物进行，以尝试提高产量改进。对 5 个 α-和 5 个 β-差向异构体 1a 和 1b 应用两步氧化路线，然后进行碱催化异构化，无论是作为混合物还是分开，得到标题化合物 5。从差向异构体 1a 获得了一个有效的过程制备所需的芳香酶抑制剂福美斯坦。差向异构体 1b 导致了相同化合物 5 的形成。此外，1b 也被转化为 5β-羟基雄甾烷-3,17-二酮 12 和雄甾醇-4-烯-3,17-二酮 13，揭示了出乎意料的反应性3 测试版，4 β-epoxy-5 β-androstan-17-one 中间体 6 在与过甲酸的第一个氧化步骤中由 1b 形成。环氧化物 6 的裂解导致了反双轴和反赤道 vic-二醇 7 和 8 以及 1,3-二醇 9。通过

  DOI：

  10.1016/s0039-128x(01)00164-7
• 作为产物：
  描述：

  3β,4β-epoxy-5β-androstan-17-one 在 甲酸 、 双氧水 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 0.5h， 以48%的产率得到3β,4α-dihydroxy-5β-androstan-17-one
  参考文献：
  名称：

  福美斯坦 5β-环氧化物前体异常环裂解的 X 射线和氘标记研究

  摘要：

  抗肿瘤类固醇福美烷 (4-OHA) 5 的新聚合合成已从 5 α-和 5 β-androst-3-en-17-one 1a 和 1b 的易于获得的差向异构混合物进行，以尝试提高产量改进。对 5 个 α-和 5 个 β-差向异构体 1a 和 1b 应用两步氧化路线，然后进行碱催化异构化，无论是作为混合物还是分开，得到标题化合物 5。从差向异构体 1a 获得了一个有效的过程制备所需的芳香酶抑制剂福美斯坦。差向异构体 1b 导致了相同化合物 5 的形成。此外，1b 也被转化为 5β-羟基雄甾烷-3,17-二酮 12 和雄甾醇-4-烯-3,17-二酮 13，揭示了出乎意料的反应性3 测试版，4 β-epoxy-5 β-androstan-17-one 中间体 6 在与过甲酸的第一个氧化步骤中由 1b 形成。环氧化物 6 的裂解导致了反双轴和反赤道 vic-二醇 7 和 8 以及 1,3-二醇 9。通过

  DOI：

  10.1016/s0039-128x(01)00164-7

文献信息

• Metabolism of 4-hydroxyandrostenedione and 4-hydroxytestosterone: Mass spectrometric identification of urinary metabolites
  作者：Maxie Kohler、Maria K. Parr、Georg Opfermann、Mario Thevis、Nils Schlörer、Franz-Josef Marner、Wilhelm Schänzer

  DOI：10.1016/j.steroids.2006.11.018

  日期：2007.3

  4-Hydroxyandrost-4-ene-3,17-dione is a second generation, irreversible aromatase inhibitor and commonly used as anti breast cancer medication for postmenopausal women. 4-Hydroxytestosterone is advertised as anabolic steroid and does not have any therapeutic indication. Both substances are prohibited in sports by the World Anti-Doping Agency, and, due to a considerable increase of structurally related steroids with anabolic effects offered via the internet, the metabolism of two representative candidates was investigated.Excretion studies were conducted with oral applications of 100mg of 4-hydroxyandro-stenedione or 200mg of 4-hydroxytestosterone to healthy male volunteers. Urine samples were analyzed for metabolic products using conventional gas chromatography-mass spectrometry approaches, and the identification of urinary metabolites was based on reference substances, which were synthesized and structurally characterized by nuclear magnetic resonance spectroscopy and high resolution/high accuracy mass spectrometry.Identified phase-I as well as phase-II metabolites were identical for both substances. Regarding phase-I metabolism 4-hydroxyandrostenedione (1) and its reduction products 3 beta-hydroxy-5 alpha-androstane-4,17-dione (2) and 3 alpha-hydroxy-5 beta-androstane-4,17-dione (3) were detected. Further reductive conversion led to all possible isomers of 3 xi,4 xi-dihydroxy,-5 xi-androstan-17-one (4, 6-11) except 3 alpha,4 alpha-dihydroxy-5 beta-androstan-17-one (5).Out of the 17 beta-hydroxylated analogs 4-hydroxytestosterone (18), 3 beta,17 beta-dihydroxy-alpha-androstan-4-one (19),3 alpha,17 beta-dihydroxy-5 beta-androstan-4-one (20), 5 alpha-androstane-3 beta,4 beta,17 beta-triol (21), 5 alpha-androstane-3 alpha,4 beta,17 beta-triol (26) and 5 alpha-androstane-3 alpha,4 alpha,17 beta-triol (28) were identified in the post administration urine specimens. Furthermore 4-hydroxyandrosta-4,6-diene-3,17-dione (29) and 4-hydroxyandrosta-1,4-diene-3,17-dione (30) were determined as oxidation products. Conjugation was diverse and included glucuronidation and sulfatation. (c) 2006 Elsevier Inc. All rights reserved.
• 17-Oxo-5α-androstane-3α,4β-diyl diacetate and 17-oxo-5β-androstane-3α,4β-diyl diacetate
  作者：L. C. R. Andrade、J. A. Paixão、M. J. M. de Almeida、F. M. Fernandes Roleira、E. J. Tavares da Silva

  DOI：10.1107/s0108270104034250

  日期：2005.3.15

  The title compounds, both C23H34O5, are the 5alpha and 5beta configurations of two diacetate epimers. The 5beta-diacetate crystallizes in an hexagonal structure, unusual for steroid molecules. The unit cell has an accessible solvent volume of 358 Angstrom(3), responsible for clathrate behaviour. The 5beta-epimer also features some shorter than average bond lengths in the 3alpha,4beta-acetoxy groups. The conformations of the molecules of both epimers are compared with those obtained through ab initio quantum chemistry calculations. Cohesion of the crystals can be attributed to van der Waals and weak molecular C-H...O interactions.